Who wants Optimer Pharmaceuticals and its high-powered antibiotics? A handful of drugmakers, apparently.
Drugmakers are circling Optimer Pharmaceuticals, the antibiotics maker that says it's considering a sale. And that includes GlaxoSmithKline, Astellas Pharma, AstraZeneca and Cubist Pharmaceuticals, Bloomberg sources say, for a deal worth as much as $1 billion.
In addition to engineering a potential sale of Optimer Pharmaceuticals, new Chairman and CEO Henry McKinnell shed more light on the alleged misdeeds involving stock grants at the highest levels of the company, Xconomy 's Bruce Bigelow reported.
Former Pfizer CEO Hank McKinnell has a new gig. He'll be running Optimer Pharmaceuticals, at least until the company finishes exploring "a full range of strategic alternatives"--a.k.a. shopping itself for sale.
Optimer Pharmaceuticals CEO Pedro Lichtinger has been shown the door, another casualty resulting from an unusual stock deal that took down the company chairman last year. And former Pfizer CEO Henry McKinnell has stepped in as interim chief while the company considers its strategic alternatives--including a possible sale.
Hank McKinnell has a new biopharma mess to sort out.
Optimer is pocketing a $20 million up-front payment on a new commercial pact for its treatment for C. difficile.
Will hospitals pay more for Optimer Pharmaceuticals' new antibiotic Dificid? That's the question, now that the FDA has given its blessing to the drug, which is the first new treatment in 25 years for
There's going to be a lot of backslapping at barbeques in San Diego this weekend. The FDA sent out word this afternoon that it's approved San Diego-based Optimer Pharmaceuticals' ($OPTR) antibiotic
As we put this edition of FierceBiotech to bed, there was still no word from the FDA on potential approval of Optimer Pharmaceuticals' antibiotic fidaxomicin (Dificid). The PDUFA date of May 30 falls